Show
Sort by
-
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients
-
- Journal Article
- A1
- open access
Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust Study
-
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients
-
Weekly Pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection
-
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels
-
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C
-
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
-
Improvement in liver histology after 3 years of E1 therapeutic vaccination in 23 patients with chronic hepatitis C
-
Hepatitis C: Screening, treatment and prevention practical guidelines
-
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C
-
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial
-
Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients
-
Chronic hepatitis B therapy with lamivudine in clinical practice - Summary of the discussion
-
HLA association of amoxicillin-clavulanate-induced hepatitis.